GlassScriptPhysician profile
Harshil B Patel
NPI 1275977555
$6,725.34
in general payments reported to CMS, 2019-2025
43 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $942 · 2021: $517 · 2022: $843 · 2023: $938 · 2024: $1,197 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,523.59 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $586.42 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $555.28 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $478.49 | 2019-2024 | Xarelto |
| Amgen INC. | $468.06 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $409.27 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $310.67 | 2021-2025 | Verquvo, Capvaxive, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.06 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $278.97 | 2019-2025 | Farxiga |
| Abiomed | $181.61 | 2023-2024 | Impella |
| Novo Nordisk INC | $161.57 | 2024-2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $155.81 | 2019-2023 | |
| Esperion Therapeutics, INC. | $115.58 | 2021-2025 | Nexletol |
| Heartflow, INC. | $113.55 | 2024-2025 | |
| Boston Scientific Corporation | $109.31 | 2023-2025 | Watchman Flx, Watchman |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harshil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.